Physician profile
Azra M Sehic
NPI 1982670808
$3,524.25
in general payments reported to CMS, 2019-2025
23 companies · $543 in 2025
The $543 reported for 2025 was more than what 77% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $417 · 2021: $504 · 2022: $395 · 2023: $599 · 2024: $356 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $749.05 | 2019-2025 | Bexsero, Penmenvy |
| Ironshore Pharmaceuticals INC. | $618.61 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $563.59 | 2019-2025 | |
| Kaleo, INC. | $277.05 | 2019-2023 | Auvi-Q |
| Cranial Technologies, INC | $175.69 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $152.86 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.42 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $135.15 | 2021-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $110.50 | 2020-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Corium, LLC | $101.97 | 2022-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $91.87 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $60.77 | 2020-2023 | |
| Genentech USA, INC. | $60.29 | 2019-2021 | |
| Organon LLC | $44.60 | 2025 | Nexplanon |
| Astrazeneca Pharmaceuticals Lp | $38.38 | 2023-2024 | Flumist Quadrivalent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $35.76 | 2019 | |
| Biofire Diagnostics, LLC | $35.73 | 2019 | |
| Neos Therapeutics, Lp | $29.87 | 2019-2020 | |
| Shire North American Group INC | $26.55 | 2019 | |
| Novo Nordisk INC | $21.07 | 2024 | Sogroya |
| Kowa Pharmaceuticals America, INC. | $17.72 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $16.48 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.27 | 2024 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azra Sehic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.